Posted inAllergy & Immunology Oncology
More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy
Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.